Krystal Biotech (NASDAQ:KRYS) Stock Price Up 7.1% After Analyst Upgrade

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) rose 7.1% during trading on Thursday after Citigroup raised their price target on the stock from $206.00 to $215.00. Citigroup currently has a neutral rating on the stock. Krystal Biotech traded as high as $186.69 and last traded at $188.63. Approximately 82,372 shares traded hands during trading, a decline of 66% from the average daily volume of 244,607 shares. The stock had previously closed at $176.17.

Several other research analysts also recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a report on Thursday. Chardan Capital lifted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $210.00.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. FMR LLC raised its holdings in Krystal Biotech by 0.5% in the 4th quarter. FMR LLC now owns 4,314,014 shares of the company’s stock worth $675,833,000 after purchasing an additional 21,133 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock worth $450,938,000 after buying an additional 28,707 shares during the period. Avoro Capital Advisors LLC lifted its holdings in Krystal Biotech by 0.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company’s stock worth $411,831,000 after buying an additional 6,600 shares during the period. State Street Corp boosted its position in shares of Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after purchasing an additional 119,936 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Krystal Biotech by 2.0% during the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after purchasing an additional 11,411 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Stock Up 2.9 %

The company has a market capitalization of $5.40 billion, a P/E ratio of 62.83 and a beta of 0.84. The company has a 50-day moving average of $157.37 and a two-hundred day moving average of $175.23.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm’s quarterly revenue was up 116.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.30 earnings per share. As a group, equities analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).